Cytokine storm in severe COVID‐19 pneumonia
| Autor: | Celal Satici, Cemile Dilsah Surmeli, Akaberk Börü, Bengul Gursoy, Berna Demirok, Mustafa Asim Demirkol, Mustafa Alkan, Sadettin Kamat, Elif Sargin Altunok |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
ARDS coronavirus Gastroenterology Procalcitonin 0302 clinical medicine 030212 general & internal medicine virus classification Research Articles medicine.diagnostic_test Macrophage Activation Syndrome Alanine Transaminase Anemia Middle Aged Troponin Intensive Care Units Cytokine release syndrome Infectious Diseases Disease Progression Female 030211 gastroenterology & hepatology Cytokine Release Syndrome Research Article medicine.medical_specialty Lymphohistiocytosis Hemophagocytic Diagnosis Differential 03 medical and health sciences Lymphopenia Virology Internal medicine medicine Humans Aspartate Aminotransferases Triglycerides Aged Retrospective Studies L-Lactate Dehydrogenase SARS-CoV-2 business.industry COVID-19 Fibrinogen medicine.disease Thrombocytopenia immnopathology immune responses Pneumonia inflammation Macrophage activation syndrome Hyperferritinemia business Cytokine storm Liver function tests Biomarkers |
| Zdroj: | Journal of Medical Virology |
| ISSN: | 1096-9071 0146-6615 |
| DOI: | 10.1002/jmv.27068 |
| Popis: | In this study, laboratorial parameters of hospitalized novel coronavirus (COVID‐19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm in some patients who needed intensive care unit (ICU), and it is aimed to determine the precursive parameters in this situation. Also in this study, the aim is to identify laboratory criteria that predict worsening disease and ICU intensification, as well as the development of cytokine storm. This article comprises a retrospective cohort study of patients admitted to a single institution with COVID‐19 pneumonia. This study includes 150 confirmed COVID‐19 patients with severe pneumonia. When they were considered as severe pneumonia patients, the clinic and laboratory parameters of this group are compared with H‐score criteria. Patients are divided into two subgroups; patients with worsened symptoms who were transferred into tertiary ICU, and patients with stable symptoms followed in the clinic. For the patients with confirmed COVID‐19 infection, after they become complicated with severe pneumonia, lymphocytopenia (55.3%), anemia (12.0%), thrombocytopenia (19.3%), hyperferritinemia (72.5%), hyperfibrinogenemia (63.7%) and elevated lactate dehydrogenase (LDH) (90.8%), aspartate aminotransaminase (AST) (31.3%), alanine aminotransaminase (ALT) (20.7%) are detected. There were no significant changes in other parameters. Blood parameters between the pre‐ICU period and the ICU period (in which their situation had been worsened and acute respiratory distress syndrome [ARDS] was developed) were also compared. In the latter group lymphocyte levels were found significantly reduced (p = 0.01), and LDH, highly sensitive troponin (hs‐troponin), procalcitonin, and triglyceride levels were significantly increased (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text